Home » Stocks » CO

Global Cord Blood Corporation (CO)

Stock Price: $5.26 USD 0.07 (1.35%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 634.06M
Revenue (ttm) 176.51M
Net Income (ttm) 77.36M
Shares Out 121.69M
EPS (ttm) 0.65
PE Ratio 8.14
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $5.26
Previous Close $5.19
Change ($) 0.07
Change (%) 1.35%
Day's Open 5.19
Day's Range 5.10 - 5.27
Day's Volume 62,936
52-Week Range 3.24 - 6.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY t...

3 weeks ago - PRNewsWire

HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processi...

1 month ago - PRNewsWire

HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...

4 months ago - PRNewsWire

The company received an acquisition offer.

4 months ago - The Motley Fool

HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...

4 months ago - PRNewsWire

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processi...

5 months ago - PRNewsWire

HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processin...

6 months ago - PRNewsWire

CO is a market leader with more net cash than the market cap and our price target is $6.00 [45% upside]. 1HFY2021 results saw total subscriber numbers grow by 10%, despite tough operating conditions.

7 months ago - Seeking Alpha

Global Cord Blood Corporation (CO) CEO Ting Zheng on Q2 2021 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

HONG KONG, Nov. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...

7 months ago - PRNewsWire

Investors who are screening for value opportunities may want to consider the following stocks since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-...

Other stocks mentioned: LRCX, RTLR
9 months ago - GuruFocus

HONG KONG, Sept. 17, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...

10 months ago - PRNewsWire

Global Cord Blood Corporation: June Quarter YoY EPS Of 22%, Subscriber Growth, And Total 183% Net Cash

10 months ago - Seeking Alpha

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q1 2021 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...

10 months ago - PRNewsWire

Global Cord Blood: 20% EPS 5-Year CAGR, 17% FCF Yield - Investing In A Business For Free

11 months ago - Seeking Alpha

HONG KONG, July 29, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...

11 months ago - PRNewsWire

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q4 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

When looking for penny stocks to buy under $5, you’ve got to go dumpster diving. That’s never an easy task when stocks aren't cheap.

Other stocks mentioned: BBAR, GTX, III, MG, NMRK, ODP, OESX ...
1 year ago - InvestorPlace

As investors continue grappling with coronavirus fears, three medical companies with high financial strength and trading below Peter Lynch’s valuation line of 15 times earnings are Bio-Rad Industries Inc.

Other stocks mentioned: BIO, FONR
1 year ago - GuruFocus

Shares of Global Cord Blood Corp. CO, -0.61% were up 0.2% in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVI...

1 year ago - Market Watch

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Global Cord Blood Corporation (CO) Management on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Global Cord Blood Corporation (CO) Management on Q4 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Cordlife is proposing to merge with Global Cord Blood in what effectively is a reverse merger and a way to list Global Cord Blood on the Singaporean stock exchange.

2 years ago - Seeking Alpha

About CO

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as C... [Read more...]

Industry
Diagnostics & Research
Stock Exchange
NYSE
Ticker Symbol
CO
Full Company Profile

Financial Performance

In 2019, CO's revenue was 1.22 billion, an increase of 23.79% compared to the previous year's 986.75 million. Earnings were 470.72 million, an increase of 61.69%.

Financial numbers in millions CNY.
Financial Statements